TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:16
BIOCRYST PHARMACEUTICALS INC ( BCRX ) https://www.biocryst.com
7.72USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
BCRX
26.77%
SPY
32.66%
-43.44%
BCRX
SPY
108.59%
BCRX
147.44%
SPY
302.52%
-36.25%
BCRX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1597.31
1584.51
1.24
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-12.90
3.87
-3.41
-3.65
0.00
89.72
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
6.57
97.24
4.05
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
11.312
2.54
2.38
1.90
Other Earnings and Cash Flow Stats:
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Net Income TTM ($MM) is -123.82
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Operating Income TTM ($MM) is -40.70
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Owners' Earnings Annual ($MM) is 0.00
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Current Price to Owners' Earnings ratio is 0.00
BIOCRYST PHARMACEUTICALS INC ( BCRX ) EBITDA TTM ($MM) is -35.97
BIOCRYST PHARMACEUTICALS INC ( BCRX ) EBITDA Margin is 4.05%
Capital Allocation:
BIOCRYST PHARMACEUTICALS INC ( BCRX ) has paid 0.00 dividends per share and bought back -17.261 million shares in the past 12 months
BIOCRYST PHARMACEUTICALS INC ( BCRX ) has increased its debt by 4.696 million USD in the last 12 months
Capital Structure:
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Interest-bearing Debt ($MM) as of last quarter is 317
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Annual Working Capital Investments ($MM) are -103
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Book Value ($MM) as of last quarter is -469
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Debt/Capital as of last quarter is -68%
Other Balance Sheet Stats:
BIOCRYST PHARMACEUTICALS INC ( BCRX ) has 96 million in cash on hand as of last quarter
BIOCRYST PHARMACEUTICALS INC ( BCRX ) has 153 million of liabilities due within 12 months, and long term debt 314 as of last quarter
BIOCRYST PHARMACEUTICALS INC ( BCRX ) has 206 common shares outstanding as of last quarter
BIOCRYST PHARMACEUTICALS INC ( BCRX ) has 0 million USD of preferred stock value
Academic Scores:
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Altman Z-Score is -2.35 as of last quarter
BIOCRYST PHARMACEUTICALS INC ( BCRX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
BIOCRYST PHARMACEUTICALS INC ( BCRX ) largest shareholder is owning shares at 0.00 ($MM) value
Hutson Nancy J(an insider) Sold 7000 shares of BIOCRYST PHARMACEUTICALS INC ( BCRX ) for the amount of $52780.00 on 2024-12-13
1.15% of BIOCRYST PHARMACEUTICALS INC ( BCRX ) is held by insiders, and 86.98% is held by institutions
BIOCRYST PHARMACEUTICALS INC ( BCRX ) went public on 1994-03-03
Other BIOCRYST PHARMACEUTICALS INC ( BCRX ) financial metrics:
FCF:-57.06
Unlevered Free Cash Flow:0.00
EPS:-0.27
Operating Margin:6.57
Gross Profit Margin:97.24
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:11.98
Beta:1.90
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BIOCRYST PHARMACEUTICALS INC ( BCRX ) :
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.